Henry Meds Lawsuit 2026: Eli Lilly’s Case, Court Rulings, and Why There’s No Payout

Quick Answer

• Yes. Eli Lilly sued Henry Meds’ operator, Adonis Health, in federal court on April 23, 2025.
• No settlement or payout exists. This is a company-versus-company case, not a patient class action.
• No claim deadline exists. Court records showed the case still active in September 2026.

The Henry Meds lawsuit is a federal false-advertising case brought by drugmaker Eli Lilly. It’s still pending. No judge has found Henry Meds liable, and no settlement has been reached.

If you’re a patient hoping for money, the answer today is no. We found no claim form, no settlement fund, and no deadline in the court record.

Before you go further, consider reading Grant Cardone Lawsuit 2026: The Investor Class Action, the $500 Million Defamation Case, and Why There’s No Claim Form

This article separates the docket from the rumors. One surprise: in September 2025, the judge threw out Lilly’s broadest claim.

Is There a Henry Meds Lawsuit, and Is It Real?

Yes. Eli Lilly sued Henry Meds’ operator, Adonis Health, in federal court on April 23, 2025.

The case is Eli Lilly and Company v. Adonis Health, Inc., No. 4:25-cv-03536-JST. It sits in the U.S. District Court for the Northern District of California. Judge Jon S. Tigar presides.

Henry Meds is the brand name. Adonis Health, Inc. is the legal entity named in court filings.

This is a civil dispute. No criminal charges and no product recall appear in the record.

Who Is Suing Henry Meds, and Who Is the Defendant?

Eli Lilly and Company is the plaintiff, and Adonis Health, Inc. is the defendant. Lilly makes Mounjaro and Zepbound, two FDA-approved tirzepatide drugs.

Lilly alleges Henry markets compounded versions of tirzepatide with misleading claims. It also targets Henry’s compounded oral tirzepatide, which Lilly calls an untested knockoff.

The complaint has three causes of action. Here is where each stands after the September 2025 ruling:

Lilly sued four telehealth companies in April 2025, including Mochi Health, Willow Health, and Fella Health. Each case moves on its own track.

Is the Henry Meds Lawsuit a Class Action?

No. The only plaintiff is Eli Lilly, a company, and no patient class exists in this case.

A class action works like a group refund for a defective batch. Many buyers share one claim. This case is closer to two competitors fighting over a billboard.

Some sites imply a certified class is coming. We found no class certification motion in the records we reviewed. One review site reported that consumer activity is limited to pre-litigation intake and mass arbitration efforts.

A separate class action was reportedly filed in November 2025 against OpenLoop Health and Triad Rx over compounded oral tirzepatide. It doesn’t involve Henry Meds.

Key Takeaway: The Henry Meds lawsuit is Lilly versus a telehealth company, not patients versus Henry Meds, so no patient class exists.

Is There a Henry Meds Settlement or Payout?

No. No settlement has been reached, and no payout exists.

The claims in the court record are Lilly’s own. It alleges lost sales and damaged goodwill. Nothing we reviewed creates a fund for patients.

A March 2026 settlement between Novo Nordisk and Hims & Hers is a separate matter. It involves different companies and creates no payment for Henry Meds customers.

Reality Check: No one is owed a Henry Meds lawsuit check right now. Sites asking you to “check eligibility” for a payout are collecting your information. Real settlements name an administrator and a deadline, and this case has neither.

Who Qualifies to Join the Henry Meds Lawsuit?

No one can join it. Lilly is the sole plaintiff, so there’s no group to enter.

You may still be connected to the case without joining it. Lilly argued in discovery that it needs patient records. The court told the parties to agree on a sample size, which Henry will then produce.

The order we reviewed doesn’t say how patient identities are protected. We couldn’t confirm that detail, so check the docket if it matters to you.

If you’re a current or former patient, your realistic options are about your own account, not this lawsuit. The next section covers them.

What Can You Do If You Have a Henry Meds Billing Problem?

You can dispute charges through your card issuer, the BBB, and your state attorney general. None of these requires joining a lawsuit.

Reviewers report that complaints cluster on billing, cancellation, and fulfillment. The BBB’s February 2026 review described the same themes, according to one site that read it.

Here are six practical steps:

1. Save order emails, receipts, and billing statements.
2. Write to Henry Meds support and keep the reply.
3. Dispute the charge with your card issuer.
4. File a complaint with the BBB.
5. File a complaint with your state attorney general.
6. Read the arbitration clause in your terms before taking further steps.

One review site that read the terms says they require individual arbitration with a class waiver. It also reports a 30-day opt-out window for new patients. Confirm both in your own terms.

Key Takeaway: There’s nothing to claim in the Lilly case, but billing disputes have separate routes through your card issuer, the BBB, and your attorney general.

What Is the Latest Henry Meds Lawsuit Update in 2026?

The latest Henry Meds lawsuit update: the case is pending and in discovery. No trial date has been confirmed.

A public court listing showed a September 1, 2026 joint case-management statement. It also showed a procedural motion on September 4. A company profile that accessed the listing on September 8, 2026 described the case as pending.

A peptide news site published an October 2026 item on the case. It noted that the excerpt it reviewed listed no new plaintiffs, claims, or rulings.

On a related note, check out Cadron Settlement Park Lawsuit 2026: Why There Is No Claim Form, No Settlement, and No Payout

What Has the Judge Ruled in the Henry Meds Lawsuit?

Judge Tigar ruled on September 24, 2025 that part of Lilly’s case could continue and part could not. He found no liability.

A motion to dismiss is a gate check, not a verdict. The judge only asked whether Lilly’s claims were plausible enough to proceed.

Henry made three arguments, and the court rejected them on the key points:

• Henry argued it doesn’t compete with Lilly. The court found both sell tirzepatide drugs to similar customers.
• Henry argued Lilly lacked standing. The court found Lilly plausibly alleged lost sales.
• Henry argued federal compounding law blocked the personalization claims. The court disagreed.

The judge dismissed Lilly’s “safe and effective” theory. He treated it as a lack-of-proof argument rather than a showing that statements were false. Lilly was allowed to amend within 21 days. Whether it did is not yet confirmed.

What Is Happening in Discovery in the Henry Meds Lawsuit?

Discovery is a fight over records. A June 2026 order told the parties to settle how many patient records Henry will produce.

The same order directed Henry to search for and produce documents tied to three physicians. That includes documents on servers belonging to an affiliated entity called Colchis. Lilly argued Henry controls those files through an administrative services agreement.

The surviving claim says Henry sells the same standard dose plan to everyone while calling it “patient-specific.” Patient records are the natural evidence for that theory.

Discovery is slow and mostly invisible. Expect motions, not headlines.

Key Takeaway: The judge let Lilly’s “personalization” claim proceed, and 2026 discovery centers on patient records.

When Will the Henry Meds Lawsuit End?

Not yet confirmed. We found no trial date and no settlement conference in the court record.

Some competing pages list class certification hearings or settlement conferences in 2026. We couldn’t match those to any docket entry.

Federal cases like this usually end in one of three ways:

• A settlement between Lilly and Henry
• A ruling on summary judgment
• A trial

None of those is scheduled in the records we reviewed. If a settlement comes, it would likely be a private deal between two companies. That wouldn’t create a patient claim process.

Is Henry Meds Still Shipping Medication?

Yes, as far as the latest sources show. We found no injunction and no recall in the records we reviewed.

A May 2026 analysis reported Henry Meds was still operating with no court order against it. A review site found that Henry continues to sell oral tirzepatide.

Think of a billboard dispute. The ad can keep running while the competitors argue in court, unless a judge orders it down.

If you’re a patient, the lawsuit itself isn’t a switch trigger. Ask your prescriber about your specific medication.

Has the FDA Taken Action Against Henry Meds?

No public FDA warning letter to Henry Meds has been confirmed. We found none.

On March 3, 2026, the FDA released a second batch of 30 warning letters to telehealth companies. Those letters targeted misleading marketing of compounded GLP-1 products. Multiple sources report Henry Meds isn’t named in either batch.

Not being named isn’t a clean bill of health. It means no public action was located.

You might also find this useful: Peachtree Settlement Funding in 2026: What the Court Dockets Actually Show About This Factoring Company

Key Takeaway: No court order, recall, or confirmed FDA warning letter has stopped Henry Meds from operating.

What Does Eli Lilly Accuse Henry Meds of?

Lilly accuses Henry of misleading advertising about compounded tirzepatide. These are allegations, not findings.

Lilly’s main claims, as summarized in the court order:

• Henry says its products contain the same active ingredient as Mounjaro and Zepbound.
• Henry’s oral tirzepatide is an untested product with no clinical data.
• Henry advertises “tailored” and “patient-specific” medication but sells one standard plan.
• Henry’s marketing refers to Lilly’s approved drugs and trials.

Henry has argued its statements were accurate. It also says it follows federal rules for compounding pharmacies.

The court has not decided who’s right on the surviving personalization claim.

What Does Compounded Tirzepatide Mean?

Compounded tirzepatide is a version of the drug mixed by a pharmacy rather than made by the original manufacturer. The court order describes compounded drugs as medicines altered to suit an individual patient.

It’s like custom-blended paint versus a store-bought can. The blend can be tailored, but nobody has tested that exact formula the way the brand’s can was tested. Lilly argues that gap matters for safety.

Lilly says no clinical trials show compounded tirzepatide is safe or effective. The judge dismissed that framing as a pleading problem, not a safety finding.

This lawsuit is not a safety recall. Your prescriber is the right person to ask about your medication.

How Is the Willow Health Case Different From the Henry Meds Lawsuit?

The Willow Health case reached a different result on a similar theory. A federal court in Los Angeles ruled for Willow on personalization on August 29, 2025.

Judge Tigar cited that ruling in a footnote and declined to follow its reasoning. Willow’s court found compliance with federal compounding rules answered the personalization claim. Tigar held that compliance was beside the point.

Same drugmaker, same theory, different courts, different outcomes. That split makes the Henry Meds case more closely watched.

It also shows why no one can predict how the Henry Meds lawsuit ends.

Key Takeaway: Two federal courts disagreed on Lilly’s personalization theory within weeks, so the outcome here isn’t predictable.

What Is Henry Meds’ BBB Rating, and Are Billing Complaints Part of the Lawsuit?

The billing complaints aren’t part of Lilly’s case. They’re a separate record.

The BBB lists Henry Meds as not accredited with an F rating. Review sites report about 227 to 228 complaints, with 26 unanswered. The BBB’s stated pattern was billing, cancellation, and fulfillment.

The picture is split. One review site counts more than 12,000 Trustpilot reviews with a high average. Another reports Trustpilot flagged the page for suspected inauthentic reviews.

A medically reviewed audit calls Henry Meds a real, licensed telehealth company with real providers and pharmacies. A real business can still draw legitimate complaints.

What Happens Next in the Henry Meds Lawsuit?

Expect slow, procedural movement. Here is the verified outlook:

• Now: Discovery continues, following the June 2026 order and September 2026 filings.
• Not yet confirmed: Summary judgment motions or a trial date.
• Not yet confirmed: Any settlement talks or a settlement conference.
• If a settlement occurs: It would appear in court filings. No patient claim process exists today.

Frequently Asked Questions

Is Henry Meds being sued?

Yes, Eli Lilly sued Adonis Health, doing business as Henry Meds, on April 23, 2025.
The case is pending in federal court in Northern California.

Can I join the Henry Meds lawsuit?

No, Lilly is the only plaintiff, so there’s nothing to join.
No claim form or deadline exists.

Is there a Henry Meds class action?

No class action against Henry Meds was found in the records we reviewed.
A separate class action reportedly targets OpenLoop Health and Triad Rx.

Did Henry Meds lose the lawsuit?

No, no court has found Henry Meds liable.
The judge dismissed Lilly’s “safe and effective” claims and kept the personalization claims.

Is Henry Meds legit?

Henry Meds is described as a licensed telehealth company, but it carries a BBB F rating.
The lawsuit is unresolved and not a recall.

Is compounded tirzepatide from Henry Meds safe?

The court made no safety finding, and no recall exists.
Ask your prescriber about your own situation.

Who is Adonis Health?

Adonis Health, Inc. is the legal entity behind the Henry Meds brand.
It’s the named defendant in the Lilly case.

If you’re a patient with a billing dispute, gather your receipts and contact your card issuer. There’s no lawsuit claim to file.

Watch the docket for case number 4:25-cv-03536-JST. As of September 2026, the case was still pending.

If you are curious, also see Types of Compensation in 2026: What Injury, Lawsuit, and Settlement Claims Actually Pay For